文献速递白血病

二代BCR-ABL1酪氨酸激酶抑制剂对比伊马替尼实现无治疗缓解的治疗价值:模型研究

Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
PubMed 文献 · Lancet Haematol · 2019-06-14

该建模研究从支付方角度评估二代BCR-ABL1酪氨酸激酶抑制剂(TKI)作为慢性髓性白血病一线治疗,对比仿制伊马替尼实现持续深度分子学反应的价值。设定5年持续深度分子学反应率伊马替尼26%、二代TKI 44%。

要点

  • 模型设定5年持续深度分子学反应率:伊马替尼26% vs 二代TKI 44%。
  • 敏感性分析中,美国当前价格或他国年价3-4万美元均无治疗价值。

核心结论

  • 在美国、欧洲和发展中国家的当前价格下,二代TKI作为一线治疗以实现持续深度分子学反应和无治疗缓解不具良好价值。

研究设计与样本

  • 决策分析模型,从支付方角度评估不同TKI策略的价值。
  • 设定5年持续深度分子学反应率:伊马替尼26%,二代TKI 44%;并模拟二代TKI 66%、88%、99%的更有利情景。

临床怎么用

  • 考虑当前二代TKI和仿制伊马替尼价格,二代TKI作为一线治疗以实现持续深度分子学反应和无治疗缓解不具良好价值。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment-free remission in chronic myeloid leukaemia-ie, achievement of a sustained deep molecular response leading to discontinuation of BCR-ABL1 tyrosine kinase inhibitor (TKI) therapy-has become a potential aim of therapy. Highly priced second-generation TKIs might offer deep molecular response status more quickly and for more patients than imatinib; however, with the availability and lower cost of generic imatinib, the value of second-generation TKIs as frontline therapy for this particular treatment endpoint remains unknown. We aimed to assess the potential value of second-generation TKIs used as frontline therapy in patients with chronic myeloid leukaemia in chronic phase in relation to the probability of achieving sustained deep molecular responses compared with generic imatinib, and the associated cost of each modality. METHODS: We used a decision analytic model to consider the value of different TKI approaches from the payer's perspective. The proportion of patients achieving sustained deep molecular response after 5 years of treatment in chronic phase was estimated at 26% with imatinib and 44% with second-generation TKIs. We also modelled more favourable scenarios of the proportion of patients achieving such response with second-generation TKIs at 66%, 88%, and a near-perfect response of 99%. For each scenario, we examined the impact of the combination of health utilities for chronic-phase chronic myeloid leukaemia (base case 0·89, range 0-1) and the annual cost of second-generation TKIs (base case US$152 814 [ie, the price of nilotinib in the USA], range 0-240 000) on the cost-effectiveness of second-generation TKIs compared with generic imatinib. We used different price scenarios for generic imatinib in the USA (average price $35 000 per year; lowest price $4400 per year), Europe ($4000 per year), and developing countries ($2100 per year). We calculated incremental cost-effectiveness ratios (ICERs) and assessed cost-effectiveness by considering two societal willingness-to-pay thresholds: $50 000 per quality-adjusted life-year (QALY) in all markets and $200 000 per QALY in the USA. FINDINGS: In the base case, we obtained an ICER of $22 765 208, meaning that second-generation TKIs as frontline therapy to achieve sustained deep molecular response was not cost-effective under either of the societal willingness-to-pay thresholds. In our sensitivity analyses, none of the explored scenarios showed potential treatment value for use of second-generation TKIs at the current prices in the USA or at the price of $30 000-40 000 per year elsewhere. For example, considering a scenario in the USA using second-generation TKIs versus imatinib (annual price $4400 per year) with the potential benefit in favour of second-generation TKI (willingness to pay $200 000 per QALY, 66% of patients achieving sustained deep molecular response, and health utility of the chronic phase of 0·1), the cost of second-generation TKIs would need to be less than $25 000 per year to be a cost-effective option. Under the same conditions in developing nations, with a price of generic imatinib of $2100 per year and a willingness to pay of $50 000 per QALY, the annual price of second-generation TKIs should not exceed $10 000 per year of therapy. INTERPRETATION: Considering the current prices of second-generation TKIs and of generic imatinib under different pricing scenarios in the USA, Europe, and developing countries, second-generation TKIs at current prices do not offer good value as frontline therapy in chronic myeloid leukaemia in order to achieve sustained deep molecular response and treatment-free remission. FUNDING: National Cancer Institute.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Shih YT, Cortes JE, Kantarjian HM, et al. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Lancet Haematol. 2019. PMID: 31208943. doi:10.1016/S2352-3026(19)30087-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。